Insight Medbotics is actively developing partnerships with companies in the AI software or accessible MRI spaces, along with therapy providers who would benefit from targeted, precision delivery.
Our Management Team, Board of Directors, and Clinical Advisory Board bring expertise in MRI, robotics, minimally-invasive surgery, radiology, oncology and private-public transactions (IPO) to Insight Medbotics.
Fazila Seker, PhD, has 20 years of experience nurturing new technologies through the commercialization process in Canada and the U.S. by building teams, raising growth funds, and bringing people together for impact in healthcare, energy, and specialty materials sectors. She has held leadership roles with the GE Global Research Center in Niskayuna, NY; MaRS Innovation and, most recently, as Co-Founder, President and CEO of MOLLI Surgical in Toronto, Canada.
Across her career, Fazila has developed a diverse portfolio of medical device opportunities with applications ranging from ultrasound to breast cancer. She also co-produced a crowd-funding campaign to promote a new medical device for monitoring breast cancer treatment. That work won national recognition in the Globe and Mail’s Top 10 Canadian crowdfunding list.
Under Fazila’s leadership, MOLLI Surgical established sales and clinical operations in the U.S. and Canada. Within four years, their efforts meant patients at some of the world’s top hospitals—such as Princess Margaret Cancer Centre in Toronto, Canada and The Christ Hospital Health Network in Ohio—were able to benefit from the company’s groundbreaking medical technology.
Building high-performance, award-winning cultures means Fazila’s teams have been recognized for their work across her career. Those accolades include Gold in the prestigious Medical Design Excellence Awards in the ER & OR (tools and supplies category); TIME Best Inventions 2022; Fast Company Next Big Things in Tech 2022; the 2021 list of Best WorkplacesTM Managed by Women; and the 2022 list of Best WorkplacesTM in Health Care.
Abhijit Saxena has 14 years of experience developing complex, innovative medical device products with deep expertise in medical robotics. His diverse portfolio spans surgical robotic, navigation and planning technologies in neurosurgical and orthopedic applications, as well as robotic and AI-based data analytics platforms in neurorehabilitation. He has a track record of launching and scaling products from technical conceptualization and development to testing and successful regulatory clearance, with a focus on markets in North America, Europe, and Asia Pacific.
Prior to joining Insight Medbotics, Abhijit was director of engineering at Intellijoint Surgical Inc., senior director of R&D at Bionik Inc., and held progressively senior engineering leadership and mechatronics development roles at Synaptive Medical Inc. Throughout his career, he has successfully scaled engineering teams and overseen portfolio development for a range of products that transform raw innovation into product adoption and additional revenue streams.
Abhijit holds a Bachelors of Engineering in Mechanical Engineering from the University of Pune and a Master of Engineering Science (MESc) in Electrical Engineering and Computer Science from Western University.
Dean Mosca has served as Insight Medbotic’s Chairman of the Board since 2019. A life-long serial entrepreneur, he was founder and CEO of Proprietary Nutritionals Inc., a nutritional supplement ingredient company specializing in business to business sales and providing clients with pioneering collaborative opportunities for cross-promotion and public education. Dean
sold the company in 2017.
Today, as CEO of Cordra Inc., Dean seeks opportunities to invest in, mentor, and offer strategic support to businesses, entrepreneurs, and start-ups developing exciting and disruptive products and technologies.
Dean is involved in various other companies and organizations as an investor or board member. He is a partner in Frontier Utility Locating Services Ltd., he sits on both the board and the investment sub-committee of Natural Products Canada, is a member of the investment selection committee for Nutrition Capital Network, and a key member in the foundation and advancement of Medbotics through his voluntary work on the board of CSii, the Canadian Centre for Surgical Invention & Innovation.
Fazila Seker, PhD, has 20 years of experience nurturing new technologies through the commercialization process in Canada and the U.S. by building teams, raising growth funds, and bringing people together for impact in healthcare, energy, and specialty materials sectors. She has held leadership roles with the GE Global Research Center in Niskayuna, NY; MaRS Innovation and, most recently, as Co-Founder, President and CEO of MOLLI Surgical in Toronto, Canada.
Across her career, Fazila has developed a diverse portfolio of medical device opportunities with applications ranging from ultrasound to breast cancer. She also co-produced a crowd-funding campaign to promote a new medical device for monitoring breast cancer treatment. That work won national recognition in the Globe and Mail’s Top 10 Canadian crowdfunding list.
Under Fazila’s leadership, MOLLI Surgical established sales and clinical operations in the U.S. and Canada. Within four years, their efforts meant patients at some of the world’s top hospitals—such as Princess Margaret Cancer Centre in Toronto, Canada and The Christ Hospital Health Network in Ohio—were able to benefit from the company’s groundbreaking medical technology.
Building high-performance, award-winning cultures means Fazila’s teams have been recognized for their work across her career. Those accolades include Gold in the prestigious Medical Design Excellence Awards in the ER & OR (tools and supplies category); TIME Best Inventions 2022; Fast Company Next Big Things in Tech 2022; the 2021 list of Best WorkplacesTM Managed by Women; and the 2022 list of Best WorkplacesTM in Health Care.
Holly Johnson is the Vice President of Robotics and Space Operations (RSO) at MDA, Canada’s leading space company that has provided robotic technology and operational support for space missions including Space Shuttle, International Space Station (ISS), and now Gateway in lunar orbit. In this role, Holly has overall responsibility for the RSO business area, which includes strategy, business development, and delivery of on-orbit robotics, sensors, and rover technologies for the global space market.
Prior to her current position, Holly led business transformation initiatives as the Vice President of Operations at MDA, working with the executive leadership team to modernize and harmonize practices and systems in human resources, finance, information technology, marketing, and business operations. During her tenure in the Operations group, Holly played a key role in the sale of MDA in 2019 to a Canadian-based private equity group and in taking MDA through its initial public offering in 2021 (TSX:MDA).
Holly has a Bachelor’s of Applied Science degree in Mechanical Engineering from the University of Toronto, and is a member of Professional Engineers Ontario. In 2023, Holly received the Best Executive award by the Globe and Mail, and in 2019 she received a Top 40 Under 40 recognition (2019), and was presented with the University of Toronto Alumni Network’s Early Career Award. Holly was also recognized for her professional accomplishments in 2016 by receipt of the Northern Lights Aero Foundation Rising Star Award. She is a passionate advocate for STEM education and women in leadership, and is an active industry representative on panels and in community events.
Since 2007, Marc Oczachowski has served as CEO, and currently also Chairman of the Board of EDAP TMS SA (Nasdaq:EDAP).
EDAP specializes in developing, manufacturing and distributing robotics and innovative medical devices based on Therapeutic Ultrasound technologies, including: HIFU (High Intensity Focused Ultrasound) as the leading modality for Prostate Cancer, and EM Shockwave lithotripsy for Kidney & Urinary stone treatments.
A French-based company with a US-listing, Marc initially secured European regulatory and clinical clearance, before relocating for 5-years to Austin, Texas to manage U.S. operations and lead the FDA approval process of the company’s HIFU devices.
He is a graduate from Lyon I University (Molecular Biology), and from Institut Commercial de Lyon (Business School), France.
Christopher is the Chief Commercial Officer of LEM Surgical AG, a Swiss company focused on developing and commercializing next generation surgical robotics platforms.
He has over 25 years of successful medical device experience in both large strategic healthcare companies and successful startup companies. A lot of Christopher’s time has been spent specifically with robotic companies seeking high growth by increasing the adoption of technology that challenges the status quo.
Prior to his most recent position, he was CEO of Harmonic Bionics, CEO of Mazor Robotics, Inc. and Chief Commercial Officer of Mazor Robotics Ltd. During his career, he has held management positions with Medtronic, Johnson & Johnson, and Tampa General Hospital.
Christopher is a West Point graduate with a master’s degree in Business Administration, as well as Healthcare Administration.
Dr. Reid’s primary clinical interest is the management and surgical treatment of breast cancer. She most recently served as the Professor & Chair of the Dept. of Surgery at McMaster University, Canada.
Dr. Reid received her MD (1987) and completed her General Surgery Residency training at McMaster University (1992), followed by a Postgraduate Fellowship in Critical Care Medicine. Dr. Reid held the John A. Bauer Chair in Surgery and in 2012 was the first female to be appointed Chair of an academic department of Surgery, in Canada. Prior to assuming that position, Dr. Reid served as the Department’s Associate Chair, Education, a role that encompassed her myriad responsibilities as Department Education Coordinator and Director of Postgraduate Surgical Training Programs.
Dr. Reid has been extensively involved in Education at the undergraduate, post-graduate, faculty and community levels as an invited speaker, instructor, advisor/mentor and a clinical and research supervisor. It was under her tutelage that a number of educational initiatives were advanced within the Department of Surgery, including the International Surgery Desk, and the Surgeon Scientist Program and the Equity, Diversity and Inclusiveness Committee. While she was Chair, the research infrastructure of the Department was enhanced, resulting in more than doubling grant and publication successes over her tenure.
Dr. Anvari, co-founder of Insight Medbotics, and thought leader in the field of Image-Guided Automated Robotics (IGAR), brings his unique skillset to the clinical advancement and approvals/clearances of the world’s first Magnetic Resonance Imaging (MRI) guided breast cancer robot.
Dr. Anvari is a tenured Professor at McMaster University. He is the founding Director of the Centre for Minimal Access Surgery (CMAS) and Scientific Director and CEO of the Centre for Surgical Invention and Innovation (CSii), affiliated with McMaster University and St. Joseph’s Healthcare Hamilton, Ontario, Canada. He is also the Editor-in-Chief of the International Journal of Medical Robotics and Computer-Assisted Surgery.
Dr. Anvari has also been awarded the Government of Ontario Diamond Award for Innovation in Technology, the Government of Canada Gold Medal of Distinction for Telerobotic Surgery, the NASA-International Space Station (ISS) Research and Development Award for Biology and Medicine (2015), and the Order of Ontario (2017).
Dr. Golatta is an Executive Senior Physician and co-head of the Senology section of the University of Heidelberg, Germany, focused on diagnostic and operative senology, and associated with the German National Cancer Institute (DKFZ).
Dr. Golatta has published widely, rapidly approaching 100 as first, last, or co-author on topics related to breast cancer diagnostics and breast surgery, including early-stage, minimally-invasive, novel clinical trials in the area of cryotherapy for breast-related diseases.
He is a current member of The German Society of Senology for minimally-invasive mammography interventions, German Association of Ultrasound in Medicine, and German Cancer Society study group of gynecological endoscopy.
Unusually, Dr. Golatta received a first degree in Economics prior to a career commitment to medicine, hence bringing a unique perspective at the nexus of business, science and medicine.
Dr. Schilling is a board-certified radiologist and the Medical Director of the Christine E. Lynn Women’s Health & Wellness Institute at the Boca Raton Regional Hospital in Boca Raton, FL, USA.
Dr. Schilling joined Boca Raton Regional Hospital in 1988 and became the Medical Director of Imaging and Intervention for the Schmidt Family Center for Breast Care at the Institute two years later. Under her stewardship, the Center has become the most experienced and comprehensive program in the region, performing over 100,000 diagnostic and therapeutic procedures a year. She now leads the medical team at the new Women’s Institute, which opened in July 2015, and provides an expanded continuum of care that addresses a woman’s unique medical needs from young adult through menopause.
An internationally-renowned radiologist and pioneering researcher in the field of women’s breast health, Dr. Schilling performed the world’s first positron emission mammography (PEM) biopsy at Boca Regional.
Dr. Schilling attended the University of Miami School of Medicine. She completed her internship at Jackson Memorial Hospital in Miami and her residency and fellowship programs at Mount Sinai Medical Center in Miami where she served as Chief Resident of Radiology. In 2001, she was awarded the coveted Wizmann Institute of Science Women of Vision Award.
She is a member of the American College of Radiology, Radiologic Society of North America, the American College of Nuclear Medicine and the Society of Breast Imaging.
Interested in a conversation?
Insight Medbotics is actively developing partnerships with companies in the AI software or accessible MRI spaces, along with therapy providers who would benefit from targeted, precision delivery.